Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606138 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
A Phase 1 study of Proliferative Diabetic Retinopathy, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00606138 is a Phase 1 study of Proliferative Diabetic Retinopathy that has completed, run by Rush University Medical Center. The registered enrollment target is 9 participants, below the 215-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00606138, a Phase 1 study of Proliferative Diabetic Retinopathy, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by the abnormal growth of blood vessels in the back of the eye, damaging the retina. The usual treatment is a type of laser, called panretinal photocoagulation. One drawback is that the amount of space within the eye for use of this treatment eventually has its limit, and should not be used too near the part of the retina used for detailed vision (the macula). In similar eye disorders, there are certain injectable medications called anti-VEGF treatments which can slow down or stop this abnormal blood vessel growth. This study sought to compare use of ranibizumab versus standard panretinal photocoagulation in treatment of diabetic neovascularization.
Conditions Studied
Interventions
- DRUG ranibizumab
- PROCEDURE Laser photocoagulation
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606138
The ClinicalTrials.gov registry entry for NCT00606138 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (96% lower). The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which ranibizumab is the first listed.
NCT00606138 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00606138 about?
NCT00606138 is a clinical study titled "Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging". Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by the abnormal growth of blood vessels in the back of the eye, damaging the retina. The usual treatment is a type of laser, called panretinal photocoagulation. One drawback is that the amount of space within the...
What is the current status of trial NCT00606138?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-01. Estimated completion is 2010-10.
What conditions does trial NCT00606138 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy.
What interventions are being tested in trial NCT00606138?
The interventions under investigation include: ranibizumab (DRUG), Laser photocoagulation (PROCEDURE).
Who is sponsoring clinical trial NCT00606138?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606138 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
COMPLETED · Phase 2
-
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.